Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Neuroendocrine Tumors 34Paraganglioma 6Meningioma 6Gastro-enteropancreatic neuroendocrine tumor 6Pheochromocytoma 5Carcinoma, Neuroendocrine 4Neuroblastoma 3Carcinoid Tumor 3Adenoma, Islet Cell 3Medulloblastoma 2Glioma 2Glioblastoma 2Ependymoma 2Carcinoma, Merkel Cell 2Carcinoma, Medullary 2Somatostatinoma 1Small Cell Lung Carcinoma 1Serotonin Syndrome 1Sarcoma, Synovial 1Recurrence 1Prostatic Neoplasms 1Pituitary Neoplasms 1Parathyroid Neoplasms 1Pancreatic Neoplasms 1Osteosarcoma 1Neoplasms, Germ Cell and Embryonal 1Neoplasms 1Metastatic Digestive System Neuroendocrine Tumor G1 1Hypertension 1Extensive Stage Small Cell Lung Cancer 1

Interventions

Lenalidomide 4Gemcitabine 4Dexamethasone 4Cyclophosphamide 4Bortezomib 4Nivolumab 3Cisplatin 3Carboplatin 3vandetanib 2tumor necrosis factor-alpha, CNGRC fusion protein, human 2pomalidomide 2pembrolizumab 2liposomal doxorubicin 2fludarabine 2durvalumab 2capivasertib 2Paclitaxel 2Doxorubicin 2Bevacizumab 2venetoclax 1umbralisib 1ublituximab 1tremelimumab 1tivozanib 1ricolinostat 1regorafenib 1pazopanib 1niraparib 1nilotinib 1neratinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Disease Progression × lutetium Lu 177 dotatate × Clear all
NCT04954820 2026-06-04

ReLUTH

Institut du Cancer de Montpellier - Val d'Aurelle

Phase 2 Recruiting
146 enrolled
EndocrineNET

Neuroendocrine Tumors, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡